A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Saved in:
| Title: | A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. |
|---|---|
| Authors: | Juric, Dejan1 (AUTHOR) juric.dejan@mgh.harvard.edu, Barve, Minal2 (AUTHOR), Vaishampayan, Ulka3 (AUTHOR), Roda, Desamparados4 (AUTHOR), Calvo, Aitana5 (AUTHOR) aitanacalvo@hotmail.com, Jañez, Noelia Martinez6 (AUTHOR), Trigo, Jose7 (AUTHOR), Greystoke, Alastair8 (AUTHOR), Harvey, R. Donald9 (AUTHOR), Olszanski, Anthony J.10 (AUTHOR), Opyrchal, Mateusz11 (AUTHOR), Spira, Alexander12,13 (AUTHOR), Thistlethwaite, Fiona14 (AUTHOR), Jiménez, Begoña7 (AUTHOR), Sappal, Jessica Huck15 (AUTHOR), Kannan, Karuppiah16 (AUTHOR), Riley, Jason17 (AUTHOR), Li, Cheryl18 (AUTHOR), Li, Cong19 (AUTHOR), Gregory, Richard C.15 (AUTHOR) |
| Source: | Cancer Medicine. Mar2024, Vol. 13 Issue 5, p1-16. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.6776 |
